Interstitial Lung Disease Within a Lung Cancer Screening

NCT04715347 | Completed

• 1 other identifier: 2017TC011
• Study Type: observational
• Target: 36
• Locations: 1 country
• Sites: 1

Brief Summary

Interstitial lung disease is a devastating lung condition with terrible outcomes. Lung cancer is the world's leading cause of cancer related death. Unlike breast and bowel cancer, there is no lung cancer screening programme in the UK. However, there are a number of pilot lung cancer screening programmes taking place including one in Manchester. The CT scans used in lung cancer screening programmes pick up other lung conditions out with lung cancer, including interstitial lung disease. This provides a unique opportunity to diagnose interstitial lung disease at an early and non-symptomatic stage where treatment can be initiated early to halt progression of disease and development of symptoms. The investigators aim to determine how much (prevalence) interstitial lung disease can be picked up in a lung cancer screening programme and how these cases would compare to those diagnosed with interstitial lung disease through the 'standard' way in the clinics. The investigators hypothesis that the patients diagnosed through the screening programmes will have an earlier stage of disease with less symptoms. If this is to be the case, this would provide researchers with the opportunity to diagnose interstitial lung disease through lung cancer screening programmes and initiate treatment early.

Conditions

Interstitial Lung Disease

Outcome Measures

Primary Outcomes (1)

• Determine the prevalence of ILD in participants of a community-based lung cancer screening programme.

  This will be determined through analysing the prevalence of ILD in participants of the MCIP lung cancer screening pilot programme

  2 years 6 months

Secondary Outcomes (11)

• Comparison of the symptom and psychological burden at diagnosis between patients diagnosed through a screening programme and patients diagnosed through routine care

  2 years

• Comparison of the quality of life between patients diagnosed through a screening programme and patients diagnosed through routine care using VAS questionnaires

  through study completion, an average of 2 years

• Comparison of the quality of life between patients diagnosed through a screening programme and patients diagnosed through routine care using FSS questionnaire

  through study completion, an average of 2 years

• Comparison of the quality of life between patients diagnosed through a screening programme and patients diagnosed through routine care using the LCQ questionnaire

  through study completion, an average of 2 years

• Comparison of the quality of life between patients diagnosed through a screening programme and patients diagnosed through routine care using the UCSD-SBQ questionnaire

  through study completion, an average of 2 years

Eligibility Criteria

• Age: 50 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Individuals attending the regional ILD clinic as a 'new referral' who have been referred from a lung cancer screening programme or through a standard non-screening pathway will be invited to participate.

You may qualify if:

• Age 50-80
• Ever-smoker
• MDT diagnosis of ILD that has been detected through lung cancer screening or standard non-screening pathway
• Attended the regional ILD clinic

You may not qualify if:

• Unable to complete self-report questionnaire measures
• Unable to provide written informed consent

Sponsors & Collaborators

• Manchester University NHS Foundation Trust: lead

Study Sites (1)

Manchester University NHS foundation trust

Manchester, Greater Manchester, M13 9WL, United Kingdom

Location

MeSH Terms

Conditions

Lung Diseases, Interstitial

Condition Hierarchy (Ancestors)

Lung Diseases; Respiratory Tract Diseases

Study Officials

• Jill Clayton-Smith, Professor

  Manchester University NHS Foundation Trust

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 27, 2020
• First Posted: January 20, 2021
• Study Start: November 11, 2017
• Primary Completion: June 30, 2020
• Study Completion: June 30, 2020
• Last Updated: July 14, 2023

Record last verified: 2023-07

Locations

GB (1)